Regional variation in prevalence of difficult-to-treat asthma and oral corticosteroid use for patients in Australia: heat map analysis. (3rd April 2023)

• Record Type: Journal Article
• Authors: Wark, Peter A. B.; Hew, Mark; Xu, Yang; Ghisla, Clare; Nguyen, Tra-My; Erdemli, Bora; Samant, Aditya; Nan, Cassandra
• Is Part Of: Journal of asthma. Volume 60:Number 4(2023)
• Page Start: 727
• Page End: 736
• Publication Date: 2023-04-03
• Subjects: Oral corticosteroids -- difficult-to-treat asthma -- uncontrolled asthma -- epidemiology; Asthma -- Periodicals; 616.238005
• DOI: 10.1080/02770903.2022.2093217
• Languages: English
• ISSNs: 0277-0903

Abstract

Abstract: Background: In Australia, the regional prevalence of difficult-to-treat asthma is unknown. We aimed to describe regional variation in difficult-to-treat asthma prevalence and oral corticosteroid (OCS) use. Methods: In this retrospective, observational, longitudinal study using data from March 2018–February 2019 in the NostraData longitudinal database, prescriptions dispensed for obstructive airway disease were processed through a high-level algorithm to identify patients with asthma. Difficult-to-treat asthma was defined by ≥2 high-dosage inhaled corticosteroids plus long-acting beta-agonist prescriptions over 6 months. Patients who additionally received OCS prescriptions sufficient to treat ≥2 exacerbations over 6 months were classified as having uncontrolled difficult-to-treat asthma. Patient-level data were analyzed across 340 geographic areas in Australia to determine regional prevalence of difficult-to-treat asthma, uncontrolled difficult-to-treat asthma, and OCS use. Results: Of 1 851 129 people defined as having asthma, 440 800 (24%) were classified as having difficult-to-treat disease. Of those difficult-to-treat asthma patients, 96 338 (22%) were considered to have uncontrolled disease. Between 29% and 48% of patients had difficult-to-treat asthma in 49 geographic areas, most frequently located in Western Australia. Between 26% and 67% of patients had uncontrolled difficult-to-treat asthma in 29 geographic areas (mostly in Eastern Australia). Overall, a wide variability of asthma severity and control was observed among regions. Conclusions: Despite global and national guidelines, regional differences in the prevalence of difficult-to-treat asthma and uncontrolled difficult-to-treat asthma and OCS use exist in Australia. Understanding these regional variations should inform policy and target management in the areas with the greatest unmet need.